Cargando…
Effectiveness of Dual Biologic or Small Molecule Therapy for Achieving Endoscopic Remission in Refractory Inflammatory Bowel Disease
Inflammatory bowel disease (IBD) is a chronic autoimmune disease with relapse–remission courses. A number of patients may present with a refractory disease with partial or no response to treatment. Others may present with extra-intestinal manifestations that makes the treatment with one biologic cha...
Autores principales: | Abdullah, Israa, AlMojil, Khaled, Shehab, Mohammad |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9680431/ https://www.ncbi.nlm.nih.gov/pubmed/36412596 http://dx.doi.org/10.3390/diseases10040102 |
Ejemplares similares
-
Effectiveness of vedolizumab and ustekinumab as second biologic agent in achieving target outcomes in tumor necrosis factor antagonists experienced patients with inflammatory bowel disease (enroll-ex study)
por: Alrashed, Fatema, et al.
Publicado: (2023) -
Breaking the Therapeutic Ceiling: Dual Biologic or Small Molecule Therapy for Refractory Inflammatory Bowel Disease
por: Ahmed, Waseem
Publicado: (2022) -
Gastroenterologists Adherence to Tumor Necrosis Factor Antagonist Combination Therapy in Inflammatory Bowel Disease
por: Abdullah, Israa, et al.
Publicado: (2021) -
Impact of medical therapies for inflammatory bowel disease on the severity of COVID-19: a systematic review and meta-analysis
por: Alrashed, Fatema, et al.
Publicado: (2021) -
Impact of biologics and small molecules for inflammatory bowel disease on COVID‐19‐related hospitalization and mortality: A systematic review and meta‐analysis
por: Alrashed, Fatema, et al.
Publicado: (2022)